FIELD: chemistry.
SUBSTANCE: invention describes tetrahydrates of pharmaceutically acceptable calcium and magnesium salts of ibersartan in crystalline form and preparation thereof in an aqueous medium of a sodium salt.
EFFECT: improved method.
4 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| S-OMEPRAZOLE STRONTIUM SALT OR HYDRATE THEREOF, METHOD OF PREPARING SAID COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS | 2006 |
|
RU2372345C1 |
| VALSARTAN SALTS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR PREPARING SALTS | 2001 |
|
RU2275363C2 |
| PHARMACEUTICALLY ACCEPTABLE THYMODEPRESSIN SALTS AND METHOD OF OBTAINING THEREOF | 2007 |
|
RU2536685C2 |
| FORM VI OF ATORVASTATIN CALCIUM AND ITS HYDRATES | 2002 |
|
RU2294924C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
| CRYSTAL HABITS | 2002 |
|
RU2334738C2 |
| CRYSTALLINE FORMS VI AND VII OF ATORVASTATIN CALCIUM SALT | 2002 |
|
RU2304139C2 |
| MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS | 2013 |
|
RU2652121C2 |
| METHOD OF PURIFYING NON-MODIFIED MONTMORILLONITE-BASED BENTONITE | 2013 |
|
RU2520434C1 |
